Vyome Holdings Inc (HIND)

$1.90 -0.08 (-4.04%)
Market Cap 13.83M
Revenue (ttm) 320,000.00
Net Income (ttm) -10.26M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,206.25%
Debt to Equity Ratio 0.00
Volume 33,590
Avg Vol 34,456
Day's Range N/A - N/A
Shares Out 7.02M
Stochastic %K 18%
Beta 1.38
Analysts Strong Sell
Price Target $11.50

Company Profile

Vyome Holdings, Inc., a clinical-stage specialty pharmaceutical company, develops therapeutic products targeting immuno-inflammatory and rare diseases in the United States. It operates through Pharmaceutical and Biotechnology segments. The company's lead product candidate VT-1953, a dual DNA Gyrase/Topoisomerase inhibitor and immunomodulator in a topical gel formulation that is in phase 2 clinical stage for the treatment of bacterial conjunctivitis. It also develops VT-1908, a topical eye drop i...

Industry: Biotechnology
Sector: Healthcare
Phone: 973-832-8147
Address:
Harvard Square, One Mifflin Place Suite 400, Cambridge, United States
BongJamesBong
BongJamesBong May. 13 at 12:12 PM
$HIND For those that missed this yesterday. https://finance.yahoo.com/sectors/healthcare/articles/vyome-strikes-deal-impetis-biosciences-120000353.html
0 · Reply
BongJamesBong
BongJamesBong May. 12 at 1:40 PM
$HIND https://finance.yahoo.com/sectors/healthcare/articles/vyome-strikes-deal-impetis-biosciences-120000353.html
0 · Reply
SamRothschild33
SamRothschild33 May. 12 at 1:33 PM
$HIND And theres the news, Like Clockwork!!! Don't be a Chump ---Time to Pump Then Immediately DUMP!!! 😂
0 · Reply
RamseysThoughts
RamseysThoughts May. 12 at 1:30 PM
$HIND — Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity https://finance.yahoo.com/sectors/healthcare/articles/vyome-strikes-deal-impetis-biosciences-120000353.html
0 · Reply
bitcoinboombust
bitcoinboombust May. 12 at 12:58 PM
$HIND 👀
0 · Reply
Love_To_Learn
Love_To_Learn May. 12 at 12:40 PM
$HIND NEED TO TURN ON YOUR 4'S SIT TIGHT
0 · Reply
Lafiha
Lafiha May. 12 at 12:33 PM
$HIND start $SPY
0 · Reply
SamRothschild33
SamRothschild33 May. 11 at 8:01 PM
$HIND $2 Gap Finally Filled... Time for the CRIMINAL Pump to Begin! Take it and Run Like Hell befor the next r/s 🚨
0 · Reply
MaximoffMACD
MaximoffMACD May. 10 at 8:41 PM
$HIND Carries the most weight in my portfolio
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 2 at 2:56 AM
$HIND RSI: 22.73, MACD: -0.0839 Vol: 0.10, MA20: 2.19, MA50: 2.42 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Latest News on HIND
Vyome signs exclusive license agreement with Impetis

2026-05-12T16:18:22.000Z - 1 day ago

Vyome signs exclusive license agreement with Impetis

Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity

May 12, 2026, 8:00 AM EDT - 1 day ago

Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity

Vyome initiated with a Buy at Litchfield Hills

2026-05-04T11:39:34.000Z - 9 days ago

Vyome initiated with a Buy at Litchfield Hills

Vyome Holdings presents Phase 2 study results on VT-1953

2026-04-22T12:37:23.000Z - 21 days ago

Vyome Holdings presents Phase 2 study results on VT-1953

Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026

Apr 22, 2026, 8:00 AM EDT - 21 days ago

Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026

Vyome Holdings to present Phase 2 data on VT-1953 at AACR 2026

2026-04-06T12:44:43.000Z - 5 weeks ago

Vyome Holdings to present Phase 2 data on VT-1953 at AACR 2026

Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026

Apr 6, 2026, 8:00 AM EDT - 5 weeks ago

Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026

Vyome Holdings reports FY25 revenue $319.7k vs $246.9k last year

2026-03-26T12:06:47.000Z - 6 weeks ago

Vyome Holdings reports FY25 revenue $319.7k vs $246.9k last year

Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

Mar 26, 2026, 8:00 AM EDT - 6 weeks ago

Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase

Vyome Holdings publishes preclinical VT-1908 data

2026-02-18T14:11:39.000Z - 3 months ago

Vyome Holdings publishes preclinical VT-1908 data

Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity

Feb 18, 2026, 9:00 AM EST - 3 months ago

Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity

Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months

Feb 11, 2026, 7:00 AM EST - 3 months ago

Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months

Vyome Holdings funds budget for VT-1953 study

2026-02-02T12:16:04.000Z - 3 months ago

Vyome Holdings funds budget for VT-1953 study

Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results

Feb 2, 2026, 7:00 AM EST - 3 months ago

Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results

Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study

Jan 27, 2026, 8:00 AM EST - 3 months ago

Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study

Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company

Dec 22, 2025, 8:00 AM EST - 5 months ago

Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company

Vyome Holdings announces VT-1953 trial achieves primary, secondary endpoints

2025-12-08T13:20:46.000Z - 5 months ago

Vyome Holdings announces VT-1953 trial achieves primary, secondary endpoints

Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval

Dec 8, 2025, 8:00 AM EST - 5 months ago

Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval

Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program

Nov 25, 2025, 7:00 AM EST - 6 months ago

Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program

Vyome Holdings Earnings Call Transcript: Q3 2025

Nov 20, 2025, 10:00 AM EST - 6 months ago

Vyome Holdings Earnings Call Transcript: Q3 2025

Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing

Nov 18, 2025, 7:00 AM EST - 6 months ago

Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing

Vyome Holdings files to sell 610K shares of common stock for holders

2025-11-06T21:25:52.000Z - 6 months ago

Vyome Holdings files to sell 610K shares of common stock for holders

Biomarker Deals Accelerate: Strategic Alliances Reshape Life Sciences Innovation

Nov 5, 2025, 10:13 AM EST - 6 months ago

Biomarker Deals Accelerate: Strategic Alliances Reshape Life Sciences Innovation

RSLS

Vyome Holdings Announces Results of Annual Shareholder Meeting

Nov 4, 2025, 9:04 AM EST - 6 months ago

Vyome Holdings Announces Results of Annual Shareholder Meeting

Vyome Holdings upgraded to Buy at Maxim on immuno-inflammatory pipeline

2025-10-02T12:55:32.000Z - 7 months ago

Vyome Holdings upgraded to Buy at Maxim on immuno-inflammatory pipeline

Vyome Holdings upgraded to Buy from Hold at Maxim

2025-10-02T11:40:07.000Z - 7 months ago

Vyome Holdings upgraded to Buy from Hold at Maxim

Vyome Holdings acquires MIT AI spinout Oculo Health

2025-09-29T11:35:05.000Z - 8 months ago

Vyome Holdings acquires MIT AI spinout Oculo Health

Vyome Holdings Acquires MIT AI Spinout Oculo Health

Sep 29, 2025, 7:00 AM EDT - 8 months ago

Vyome Holdings Acquires MIT AI Spinout Oculo Health

Vyome Stock (HIND) Rockets on Uveitis Study Data

2025-09-17T12:54:52.000Z - 8 months ago

Vyome Stock (HIND) Rockets on Uveitis Study Data

Vyome Holdings presents results from VT-1908 preclinical studies

2025-09-17T11:15:22.000Z - 8 months ago

Vyome Holdings presents results from VT-1908 preclinical studies

Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity

Sep 17, 2025, 7:00 AM EDT - 8 months ago

Vyome Presents Strong Data Showing Topical VT-1908 is an Effective Treatment for Uveitis, Opening Up a $3B Addressable Market Opportunity

Vyome Holdings appoints Richard Fahrner as CTO

2025-09-09T13:11:19.000Z - 8 months ago

Vyome Holdings appoints Richard Fahrner as CTO

Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies

Sep 9, 2025, 8:30 AM EDT - 8 months ago

Vyome Holdings Strengthens Leadership Team with Industry Veterans as it plans Pivotal Trial Studies

Vyome Holdings announces positive interim data from VT-1953 Phase 2 study

2025-09-04T13:10:45.000Z - 8 months ago

Vyome Holdings announces positive interim data from VT-1953 Phase 2 study

Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity

Sep 4, 2025, 8:30 AM EDT - 8 months ago

Vyome Holdings Announces Positive Interim Data from Phase 2 Study of VT-1953 in Malignant Fungating Wounds (MFW) and Provides Update on MFW market opportunity

Vyome Holdings, Embryyo Technologies sign MoU for AI-enabled medical devices

2025-08-21T11:15:26.000Z - 9 months ago

Vyome Holdings, Embryyo Technologies sign MoU for AI-enabled medical devices

Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio

Aug 21, 2025, 7:00 AM EDT - 9 months ago

Vyome Signs MoU with Embryyo, India's Leading Medical Device Innovation Studio

Vyome Announces Strategic Review of Livechain (OTCID: LICH)

Aug 18, 2025, 8:30 AM EDT - 9 months ago

Vyome Announces Strategic Review of Livechain (OTCID: LICH)

Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell

Aug 15, 2025, 8:00 AM EDT - 9 months ago

Vyome To Mark First Day of Trading as HIND with Nasdaq Opening Bell

Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow

Aug 14, 2025, 7:18 PM EDT - 9 months ago

Vyome closes Merger Transaction, Will Trade on Nasdaq as HIND Tomorrow

RSLS

Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

Aug 13, 2025, 11:50 AM EDT - 9 months ago

Vyome Announces Nasdaq Approval of Merger with ReShape Lifesciences, Set to Begin Trading as HIND

RSLS

Vyome Announces New Board of Directors with Deep MIT and AI Ties

Aug 12, 2025, 9:48 AM EDT - 9 months ago

Vyome Announces New Board of Directors with Deep MIT and AI Ties

RSLS

ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics

Aug 7, 2025, 5:01 PM EDT - 9 months ago

ReShape Lifesciences Announces Shareholder Approval of Merger with Vyome Therapeutics

RSLS

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

Jul 24, 2025, 4:39 PM EDT - 10 months ago

ReShape Lifesciences® Announces Partial Adjournment of Special Meeting of Stockholders

RSLS

ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit

Jul 22, 2025, 8:31 AM EDT - 10 months ago

ReShape Lifesciences® to Host Inaugural Lap-Band® Surgeon Summit

RSLS

ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025

Jul 21, 2025, 2:10 PM EDT - 10 months ago

ReShape Lifesciences® to Host Special Meeting of Stockholders on July 24, 2025

RSLS

ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System

Jul 1, 2025, 8:31 AM EDT - 11 months ago

ReShape Lifesciences® Granted U.S. Patent Related to an Intragastric Balloon System

RSLS

ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement

Jun 27, 2025, 9:01 AM EDT - 11 months ago

ReShape Lifesciences® Regains Compliance with Nasdaq Minimum Stockholders Equity Requirement

RSLS

ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys

Jun 26, 2025, 8:31 AM EDT - 11 months ago

ReShape Lifesciences® Announces Strategic Cost Reductions and Provides Update on the Merger Agreement with Vyome Therapeutics and Asset Purchase Agreement with Biorad Medisys

RSLS

ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology

Jun 25, 2025, 8:31 AM EDT - 11 months ago

ReShape Lifesciences® Granted Key International Patent in Australia for Its Proprietary Diabetes Neuromodulation Technology

RSLS

ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets

Jun 12, 2025, 8:25 AM EDT - 11 months ago

ReShape Lifesciences® Signs Exclusive Distribution Agreement with Recon Supply to Access the VA and DoD Markets

RSLS

ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering

Jun 9, 2025, 9:00 AM EDT - 1 year ago

ReShape Lifesciences® Announces Pricing of $2.6 Million Public Offering

RSLS

ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio

Jun 3, 2025, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Announces EU MDR Certification for Entire European and United Kingdom Product Portfolio

RSLS

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

May 21, 2025, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Reports First Quarter Ended March 31, 2025 Financial Results and Provides Corporate Update

RSLS

ReShape Lifesciences Announces 1-for-25 Reverse Stock Split

May 7, 2025, 8:31 AM EDT - 1 year ago

ReShape Lifesciences Announces 1-for-25 Reverse Stock Split

RSLS

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium

May 2, 2025, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Presents Pre-clinical Data on Its Proprietary Diabetes Neuromodulation Device at the 12th Annual Minnesota Neuromodulation Symposium

RSLS

ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System

Apr 28, 2025, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Receives Notice of Allowance for Key U.S. Patent Related to an Intragastric Balloon System

RSLS

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

Apr 21, 2025, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Receives Notice of Allowance for Additional U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

RSLS

ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

Apr 9, 2025, 4:05 PM EDT - 1 year ago

ReShape Lifesciences® Partners with Motion Informatics to Bring AI-Driven Neurorehabilitation Technology to the U.S. Market

RSLS

ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

Apr 7, 2025, 4:05 PM EDT - 1 year ago

ReShape Lifesciences® Reports Year Ended December 31, 2024 Financial Results and Provides Corporate Update

RSLS

RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS

Mar 21, 2025, 11:35 AM EDT - 1 year ago

RESHAPE LIFESCIENCES INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of ReShape Lifesciences Inc. - RSLS

RSLS

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

Mar 10, 2025, 8:31 AM EDT - 1 year ago

ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to Its Proprietary Diabetes Neuromodulation Technology

RSLS

ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX

Feb 25, 2025, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Signs Distribution Agreement in Canada With Liaison Medical for its Next-Generation Lap-Band® 2.0 FLEX

RSLS

ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

Feb 15, 2025, 11:17 PM EST - 1 year ago

ReShape Lifesciences® Announces Pricing of Upsized $6.0 Million Public Offering

RSLS

ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology

Feb 3, 2025, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Granted Key International Patent in Israel for Its Proprietary Diabetes Neuromodulation Technology

RSLS

ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

Jan 13, 2025, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Provides Update on Merger Agreement With Vyome Therapeutics and Asset Purchase Agreement With Biorad Medisys

RSLS

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

Nov 12, 2024, 4:05 PM EST - 1 year ago

ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate Update

RSLS

ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX

Nov 12, 2024, 8:31 AM EST - 1 year ago

ReShape Lifesciences® Receives Health Canada Approval for its Next-Generation Lap-Band® 2.0 FLEX

RSLS

BongJamesBong
BongJamesBong May. 13 at 12:12 PM
$HIND For those that missed this yesterday. https://finance.yahoo.com/sectors/healthcare/articles/vyome-strikes-deal-impetis-biosciences-120000353.html
0 · Reply
BongJamesBong
BongJamesBong May. 12 at 1:40 PM
$HIND https://finance.yahoo.com/sectors/healthcare/articles/vyome-strikes-deal-impetis-biosciences-120000353.html
0 · Reply
SamRothschild33
SamRothschild33 May. 12 at 1:33 PM
$HIND And theres the news, Like Clockwork!!! Don't be a Chump ---Time to Pump Then Immediately DUMP!!! 😂
0 · Reply
RamseysThoughts
RamseysThoughts May. 12 at 1:30 PM
$HIND — Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity https://finance.yahoo.com/sectors/healthcare/articles/vyome-strikes-deal-impetis-biosciences-120000353.html
0 · Reply
bitcoinboombust
bitcoinboombust May. 12 at 12:58 PM
$HIND 👀
0 · Reply
Love_To_Learn
Love_To_Learn May. 12 at 12:40 PM
$HIND NEED TO TURN ON YOUR 4'S SIT TIGHT
0 · Reply
Lafiha
Lafiha May. 12 at 12:33 PM
$HIND start $SPY
0 · Reply
SamRothschild33
SamRothschild33 May. 11 at 8:01 PM
$HIND $2 Gap Finally Filled... Time for the CRIMINAL Pump to Begin! Take it and Run Like Hell befor the next r/s 🚨
0 · Reply
MaximoffMACD
MaximoffMACD May. 10 at 8:41 PM
$HIND Carries the most weight in my portfolio
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser May. 2 at 2:56 AM
$HIND RSI: 22.73, MACD: -0.0839 Vol: 0.10, MA20: 2.19, MA50: 2.42 🟢 BUY - Uptrend + healthy RSI 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Flarelords
Flarelords Apr. 30 at 4:17 PM
$HIND
0 · Reply
SabrinaCarpenterFan
SabrinaCarpenterFan Apr. 28 at 4:17 PM
$HIND
0 · Reply
SillySallySonders
SillySallySonders Apr. 27 at 4:17 PM
$HIND
0 · Reply
AnthonyTradingWithJesus
AnthonyTradingWithJesus Apr. 26 at 10:22 PM
$GBTC $HIND $DIS $DJT $NVDA
0 · Reply
Tech4lyfe
Tech4lyfe Apr. 26 at 4:17 PM
$HIND
0 · Reply
WaltersWhite
WaltersWhite Apr. 25 at 4:17 PM
$HIND
0 · Reply
KhanAcademylol
KhanAcademylol Apr. 24 at 4:17 PM
$HIND
0 · Reply
EmielTheBlessed
EmielTheBlessed Apr. 23 at 4:16 PM
$HIND
0 · Reply
focafoca99
focafoca99 Apr. 22 at 6:36 PM
$HIND Vyome presented phase 2 VT-1953 clinical data at AACR 2026. https://www.rapidticker.com/news/hind-vyome-presents-transformational-vt-1953-f809e9
0 · Reply
LebronBOOM
LebronBOOM Apr. 22 at 1:30 PM
$HIND — Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026 https://finance.yahoo.com/sectors/healthcare/articles/vyome-presents-transformational-vt-1953-120000941.html
0 · Reply
Eatmon
Eatmon Apr. 21 at 4:16 PM
$HIND
0 · Reply
Hugoooo
Hugoooo Apr. 21 at 1:57 PM
$HIND no news
1 · Reply